Publications by authors named "David Yoannidis"

Article Synopsis
  • Therapeutic strategies focusing on disrupting dysregulated transcription have shown promise for treating cancers like leukaemias using small molecule inhibitors that target key proteins involved in gene expression.* -
  • Research indicates that the effectiveness of these inhibitors is influenced not just by their ability to stop mRNA production, but also by how quickly mRNA is produced and degraded.* -
  • Findings suggest that modifying post-transcriptional processes, such as targeting specific proteins, can enhance the effects of transcriptional inhibitors, offering potential new combination therapies for leukaemia.*
View Article and Find Full Text PDF

Transcriptomic profiling has fundamentally influenced our understanding of cancer pathophysiology and response to therapeutic intervention and has become a relatively routine approach. However, standard protocols are usually low-throughput, single-plex assays and costs are still quite prohibitive. With the evolving complexity of in vitro cell model systems, there is a need for resource-efficient high-throughput approaches that can support detailed time-course analytics, accommodate limited sample availability, and provide the capacity to correlate phenotype to genotype at scale.

View Article and Find Full Text PDF

High-throughput methodologies are the cornerstone of screening approaches to identify novel compounds that regulate immune cell function. To identify novel targeted therapeutics to treat immune disorders and haematological malignancies, there is a need to integrate functional cellular information with the molecular mechanisms that regulate changes in immune cell phenotype. We facilitate this goal by combining quantitative methods for dissecting complex simultaneous cell phenotypic effects with genomic analysis.

View Article and Find Full Text PDF

The mitochondrial enzyme dihydroorotate dehydrogenase (DHODH) catalyzes one of the rate-limiting steps in de novo pyrimidine biosynthesis, a pathway that provides essential metabolic precursors for nucleic acids, glycoproteins, and phospholipids. DHODH inhibitors (DHODHi) are clinically used for autoimmune diseases and are emerging as a novel class of anticancer agents, especially in acute myeloid leukemia (AML) where pyrimidine starvation was recently shown to reverse the characteristic differentiation block in AML cells. Herein, we show that DHODH blockade rapidly shuts down protein translation in leukemic stem cells (LSCs) and has potent and selective activity against multiple AML subtypes.

View Article and Find Full Text PDF